Lithium Citrate Anhydrous

Summary

Lithium Citrate Anhydrous (CHEMBL1201170) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 210 Da · C6H5Li3O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201170
Name	Lithium Citrate Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	13520
ChEBI	CHEBI:64735
Molecular formula	C6H5Li3O7
Molecular weight	210
InChIKey	WJSIUCDMWSDDCE-UHFFFAOYSA-K

SMILES: [Li+].[Li+].[Li+].C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O

IUPAC name: trilithium;2-hydroxypropane-1,2,3-tricarboxylate

ChEBI definition: A lithium salt that is the anhydrous form of the trilithium salt of citric acid. The tetrahydrate form is used as a source of lithium for the treatment of anxiety disorders, bipolar disorder, and depression.

Also known as: Citric acid trilithium salt, Lithium citrate anhydrous

Parent form; salt/anhydrous children: CHEMBL2103738

Patent coverage: 2,906 distinct patent families (8,137 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).